Merck’s Allergy Immunotherapy Suffers Review Delay Under Gov’t Shutdown
This article was originally published in The Pink Sheet Daily
Executive Summary
Without user fee coverage, advisory committees for Merck and Stallergenes’ new era grass allergy products must be pushed back from their scheduled November dates.